TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants With a PASI75 Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Discontinuing Study Treatment Due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients without progression at month 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ocular manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No surgical reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: No worsening of Cobb angle by more than 15 degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of solicited injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of solicited injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of solicited systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of solicited systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration-time Curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) from the time of dosing to the last measurable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerable dose of sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of Pulmonary Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Measurement of Respiratory Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Measurement of Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Measurement of Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Clot strength (Maximum Clot Firmness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of Zika virus-specific immunoglobulin G antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rates of device-and procedure-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in executive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: proportion of subjects with plasma HIV-1 RNA <50 c/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Healthcare Workers Testing Positive for COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Patients Testing Positive for COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Community Participants Testing Positive for COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Oral Motor Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Eating Assessment Tool- Pedi EAT
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pediatric Eating Assessment Tool
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hepatic Veno-Occlusive Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Standing Dose of Norepinephrine to Maintain MAP of 65 mmHg - Hour 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standing Dose of Norepinephrine to Maintain MAP of 65 mmHg - Hour 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to sustained improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility and acceptability of intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hormonal changes during weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Metabolic changes during weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in breath-by-breath variability of tidal breathing amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in behavioral measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak plasma concentration of sitaxsentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of sitaxsentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Day 0 in Performance on the Cambridge Neuropsychological Test Automated Batteries Spatial Working Memory (CANTAB SWM) Strategy Score at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance time at 75% of maximal workout
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients adhering to treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: joint score evaluated by clinical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint score evaluated by ultra-sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of high doses of zinc
Endpoint domain: Adverse events/effects
Primary endpoint: Fatty Acid Synthase Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell Proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional computational model outcome parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pulse oxymetry (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Guideline-directed medical therapy (GDMT) adoption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac allograft vasculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in area under the plasma concentration time curve (AUC) of escitalopram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of pelvic organs prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of Epistaxis
Endpoint domain: Adverse events/effects
Primary endpoint: First Occurrence of CV Death / MI / Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Mean percent change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Post-dose (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Profile From Time Zero to Infinity (AUC 0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distance walked during the 6-minute walk test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural major adverse cardiac events (pMACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Thighs Circumference Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion detection of early gastric cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: status of tumor / metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: patient's performance status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOL) assessment by the patient
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nepean Dyspepsia Index (NDI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PROMIS Global Health Measure Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Psychological Flourishing Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: UCLA Loneliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: rate of adequate cleansing level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants with a Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in median pain VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Smoking Abstinent in Past 7 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of Cigarettes Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Relapse to Any Heavy Drinking
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Relapse to Any Drug Use
Endpoint domain: Adverse events/effects
Primary endpoint: Phenotype measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in physical inactivity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Levels of circulating EVs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of islet-specific antigens in EVs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of samples with a positive diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Primary success rate of SNS after 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PCr/ATP Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: impulsive tendency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pathological complete and subtotal regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women with mature follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Patient reported gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Activity Participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Increased Mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: maintenance of continuous care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Children's Anxiety Level Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Near Best Corrected Visual Acuity (BCVA) - Binocular
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Uncorrected Visual Acuity (UCVA) Binocular
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Best Corrected Visual Acuity Left Eye (BCVA LE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Uncorrected Visual Acuity Left Eye (UCVA LE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Best Corrected Visual Acuity Right Eye (BCVA RE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain - Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain - Comparative Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Postoperative Air Leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of Prolonged Air Leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to first occurring event of all-cause death, ESRD, and eGFR-loss >40%
Endpoint domain: Mortality/survival
Primary endpoint: Incremental number of dental surfaces with operative treatment needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants no longer meeting PTSD criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD/RP2D of CD22-CAR T cells in subjects with aggressive B-cell NHL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety evaluation of CD22-CAR T cells in subjects with ALL
Endpoint domain: Adverse events/effects
Primary endpoint: Mean difference in HOMA-IR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of clinical features predictive of poor outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of Community Resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Provider Referrals for Unmet Material Needs at Visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Healthy Eating Index-2015 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients With a Positive Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiologist ROC AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in muscle ultrasound echointensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in muscle electrical impedance myography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Response Defined as a 75% or Greater Change in Number of Average Weekly FI Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants with Specified Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Costs
Endpoint domain: Resource use
Primary endpoint: Cmax - Maximum Observed Plasma BIA 2-194 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 year Event Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Sternal Wound Infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Local-regional recurrence (LRR)
Endpoint domain: Mortality/survival
Primary endpoint: Aesthetic & Functional total score (Patient edition)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EQ-5D-5L total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: disease-related episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in IRLSSG Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coping (Effective Consumer Scale (EC17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 30 second sit to stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical margin status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CKD stage upgrading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Control Preference Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-Physician Interactions Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Decision Self Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patients' Perceived Involvement in Care Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of poor graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of prolonged isolated thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnostic values of EBUS-TBNA plus EUS-B-FNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hierarchical Composite Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expanded Disability Status Scale (EDSS) value
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to Initial Clinical Resolution of Norovirus Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in manual muscle strength (MMT) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients developing operational tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal Respiratory Distress Syndrome (RDS) at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change of interferon-gamma production by peripheral blood mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intensive Care Unit admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative mechanical support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants with Grade 2 or Higher Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose Reductions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median Time to First Dose Reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: BOLD signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate (CR, PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of oral CP-4126
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of oral CP-4126
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Sleep Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change of pCO2 in arterial blood gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Local Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Il-18 levels in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Il-18 levels in endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histamine levels in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histamine levels in endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GLUT4 levels in endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Resolution of Hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in net whole body protein balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL-cholesterol < 70 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Type and Severity of Adverse Effects and Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Microbial translocation measured by soluble CD14 (sCD14)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Ewing/Peripheral PNET Participants With Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: EMDR protocol completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-bearing deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: physiologic costs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of dilation of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: polysomnography measures of sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: polysomnography measures of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Peak alpha frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes